How good do current LHRH agonists control testosterone? Can this be improved with Eligard®?

European Urology, Supplements

Volumn 4, Issue 8, 2005, Pages 30-36

  Tombal, Bertrand ^a   Berges, Richard ^b  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^b PAN Klinik am Neumarkt   (Germany)

Author keywords

Acute on chronic response; Breakthrough response; Castration level; Eligard ; Hormone therapy; LHRH agonist; Prostate cancer; Testosterone suppression

Indexed keywords

GONADORELIN AGONIST; GOSERELIN; LEUPRORELIN; POLYGLACTIN; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

BURNING SENSATION; CANCER GROWTH; CASTRATION; CLINICAL TRIAL; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GYNECOMASTIA; HOT FLUSH; HUMAN; INJECTION SITE REACTION; MALAISE; NAUSEA; ORCHIECTOMY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SUSTAINED DRUG RELEASE; TESTIS ATROPHY; TESTOSTERONE BLOOD LEVEL;

EID: 26444564275     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2005.08.004     Document Type: Article

References (29)

1. C. Huggins, and C.V. Hodges Studies on prostatic cancer. I. The effects of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. D.P. Byar, and D.K. Corle Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies NCI Monogr 7 1988 165 170
3. A.V. Schally, A.J. Kastin, and A. Arimura Hypothalamic FSH and LH-regulating hormone. Structure, physiology and clinical studies Fertil Steril 22 1971 703 721
4. The Leuprolide Study Group Leuprolide versus diethylstilbestrol for metastatic prostate cancer N Engl J Med 311 1984 1281 1286
5. L.M. Gommersall, D. Hayne, I.S. Shergill, M. Arya, and D.M.A. Wallace Luteinising hormone releasing hormone analogues in the treatment of prostate cancer Expert Opin Pharmacother 3 2002 1685 1692
6. M.G. Oefelein, and M.I. Resnick Effective testosterone suppression for patients with prostate cancer: is there a best castration? Urology 62 2 2003 207 213
7. M.G. Oefelein, A. Feng, M.J. Scolieri, D. Ricchiutti, and M.I. Resnick Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making Urology 56 2000 1021 1024
8. A.V. Kaisary, C.J. Tyrrell, W.B. Peeling, and K. Griffiths Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma Br J Urol 67 5 1991 502 508
9. H.F. Rohl, and H.P. Beuke Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer Scand J Urol Nephrol 26 1 1992 11 14
10. B.J. Lin, K.K. Chen, M.T. Chen, and L.S. Chang The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer Urology 43 6 1994 834 837
11. N.J. Vogelzang, G.W. Chodak, M.S. Soloway, N.L. Block, P.F. Schellhammer, and J.A. Smith Jr. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group Urology 46 2 1995 220 226
12. Zlotta A, Debruyne F. Expert opinion on optimal testosterone control in Prostate Cancer. Eur Urol Suppl. 2005;(4):37-41.
13. S. Esquena, J.M. Abascal, E. Trilla, and J. Morote Failure of luteinising hormonal releasing hormonal agonist therapy to achieve castration. Does it exist? Eur Urol Suppl 3 2004 57 (abs. 218)
14. Morote J. In Press.
15. M.G. Oefelein, and R. Cornum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 3 Pt 1 2000 726 729
16. H.W. Wechsel, M. Zerbib, F. Pagano, and M.J. Coptcoat Randomized open labelled comparative study of the efficacy, safety and tolerability of leuprorelin acetate 1M and 3M depot in patients with advanced prostatic cancer Eur Urol 30 Suppl. 1 1996 7 14
17. D. McLeod, N. Zinner, K. Tomera, D. Gleason, N. Fotheringham, M. Campion Abarelix Study Group A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer Urology 58 5 2001 756 761
18. J. Kawakami, and A. Morales J Urol 167 Suppl. 4 2002 288 (abs. 1135)
19. G.J. Bubley Is the flare phenomenon clinically significant? Urology 58 2 Suppl. 1 2001 5 9
20. R. Sharifi, R. Browneller Leuprolide Study Group Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer J Urol 168 2002 1001 1004
21. M.F. Sarosdy, P.F. Schellhammer, M.S. Soloway, N.J. Vogelzang, E.D. Crawford, and J. Presti Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every13 weeks to patients with advanced prostate cancer BJU Int 83 1999 801 806
22. N. Zinner, M. Bidair, A. Centeno, and K. Tomera Similar frequency of testosterone surge after repeat injections of goserelin (Zoladex) 3.6 mg and 10.8 mg: results of a randomized open-label trial Urology 64 2004 1177 1181
23. D. Fontana, M. Mari, A. Martinelli, C. Boccafoschi, C. Magno, and M. Turriziani 3-month formulation of goserelin acetate (Zoladex) in advanced prostate cancer: results from an Italian open multicentre trial Urol Int 70 2003 316 320
24. M.S. Khan, and A. O'Brien An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate Urol Int 60 1998 33 40
25. D. Jocham Leuprorelin three-month depot in the treatment of advanced and metastatic prostate cancer: long-term follow-up results Urol Int 60 Suppl 2 1998 18 24
26. Tombal B. Data on file.
27. F.M. Chu, M. Jayson, M.K. Dineen, R. Perez, R. Harkaway, and R.C. Tyler A clinical study of 22.5 mg LA-2550: a new subcutaneous depot delivery system for leuprolide acetate for the treatment of prostate cancer J Urol 168 2002 1199 1203
28. R. Perez-Marreno, F.M. Chu, D. Gleason, E. Loizides, B. Wachs, and R.C. Tyler A six-month, open-label study assessing a new formulation of leuprolide 7.5 mg for suppression of testosterone in patients with prostate cancer Clin Ther 24 2002 1902 1914
29. R. Perez-Marreno, and R.C. Tyler A subcutaneous delivery system for the extended release of leuprolide acetate for the treatment of prostate cancer Expert Opin Pharmacother 5 2004 447 457